Welcome to our dedicated page for CDT Equity news (Ticker: CDT), a resource for investors and traders seeking the latest updates and insights on CDT Equity stock.
CDT Equity Inc. develops and repositions biopharmaceutical assets through a data-driven model that combines licensed clinical compounds, solid-form chemistry, cocrystal intellectual property and out-licensing. News about CDT commonly covers its AZD1656, AZD5658 and AZD5904 assets, patent filings, therapeutic-indication analysis, and programs spanning autoimmune disorders, idiopathic male infertility, dermatology, oncology, rare disease and animal health.
Company updates also include CDT's 20% equity interest in Sarborg Limited, whose Signature Agent, Multi-Agent and Signature Intelligence platforms are used for disease mapping and therapeutic-opportunity identification. Other recurring items include stockholder votes, Nasdaq capital-structure actions, warrants and equity financing arrangements.
CDT Equity (Nasdaq: CDT) reported receipt of a Nasdaq deficiency letter after not timely filing its Form 10-Q for the quarter ended March 31, 2026, as required by Nasdaq Listing Rule 5250(c)(1).
The notice does not immediately affect listing or trading. CDT has until July 20, 2026 to submit a compliance plan and expects to file the Form 10-Q once its review is complete.
CDT Equity (Nasdaq: CDT) received a Canadian patent covering the use of AZD5904 in male infertility, completing protection in key pharmaceutical target markets. The company views this, together with a composition of matter application, as reinforcing its IP position while it advances licensing and strategic partnering discussions.
AZD5904, originally licensed from AstraZeneca, has an extensive clinical safety package and pre-clinical validation in a male infertility market estimated at about USD $4.4 billion annually with no approved drug therapies.
CDT (Nasdaq: CDT) notes Sarborg Limited filed a new Substance of Matter (SOM) patent covering two established cystic fibrosis compounds on May 7, 2026. Sarborg says the patent used its Signature Agent and Multi-Agent platform and was filed in less than three weeks.
CDT holds a 20% stake in Sarborg and says it will evaluate combination opportunities between its assets and the compounds in the filing to expand intellectual property and commercial options.
CDT (Nasdaq: CDT) advanced AZD5904 into the PCT (global patent) phase and has begun partnering discussions to out-license the asset for later-stage development. AZD5904 has clinical safety data from 181 subjects across five Phase 1 studies and currently holds composition-of-matter and method-of-use patents for idiopathic male infertility.
The company cites favourable safety, pre-clinical mechanistic support, and an expanded IP strategy as reasons to pursue global protection and strategic pharma partnerships.
CDT (Nasdaq: CDT) updated its strategy on April 16, 2026, positioning as a multi-pathway value-creation business combining a pharmaceutical asset portfolio, proprietary solid-form IP and AI-driven indication discovery.
The company is advancing AstraZeneca-licensed assets (AZD1656, AZD5658, AZD5904), expanding solid-form IP, and leveraging a 20% stake in Sarborg for AI signature-driven indication selection to accelerate partner-ready licensing packages.
CDT (Nasdaq: CDT) notes Sarborg's April 7, 2026 publication of PRISM, a cross-species connectivity mapping framework applying transcriptomic signature comparison to plant biology.
CDT holds a 20% equity interest in Sarborg and believes PRISM extends Sarborg's Signature Intelligence platform into agrichemical and industrial biology domains.
CDT Equity (Nasdaq: CDT) filed two patent applications on March 26, 2026, expanding its tapinarof intellectual property portfolio.
One patent covers a tapinarof combination therapy with a class of drugs used in psoriasis and atopic dermatitis; the other covers novel tapinarof cocrystal forms. CDT says these filings may support a second-generation product, extend lifecycle, broaden clinical scope, and enable out-licensing opportunities.
CDT Equity (Nasdaq: CDT) announced a 1-for-25 reverse stock split effective March 26, 2026 at 5:00 pm ET, with shares expected to trade on a split-adjusted basis on Nasdaq at market open on March 27, 2026. As a result, every 25 issued and outstanding shares will combine into one share, reducing outstanding shares to approximately 4,722,450.
Par value remains $0.0001. Proportional adjustments apply to equity awards, convertible securities, warrants, and shares reserved under equity incentive plans. No fractional shares will be issued; cash payments will be made instead. The new CUSIP will be 20678X502.
CDT (Nasdaq: CDT) completed initial signature mapping of its asset portfolio against Sarborg's AI-curated rare disease database, identifying multiple statistically significant matches across immunology, oncology, infectious disease, paediatric and ophthalmology.
The analysis evaluated CDT assets including its solid-form patent portfolio and licensed AstraZeneca compounds AZD1656 and AZD5658 against about 1,700 rare-disease signatures. CDT plans targeted preclinical validation to build out datasets for early-stage out-licensing discussions.
CDT Equity (Nasdaq: CDT) announced stockholders approved all proposals at the Special Meeting held March 17, 2026. Key highlights include a $123M investment in Sarborg, expansion of the company IP portfolio, potential access to new capital, and a targeted annual overhead of less than $8 million.
The company says its AI-driven platform can analyze more than 3,000 diseases in hours versus conventional timelines, and CDT is shifting toward out-license deals with disease-specific partners and funds.